New gene therapy injected into spine aims to fight devastating ALS
NCT ID NCT07169175
Summary
This is an early-stage trial testing a new gene therapy called SNUG01 for adults with Amyotrophic Lateral Sclerosis (ALS). The main goal is to see if the treatment is safe and tolerable when injected into the spinal fluid. Researchers will also look for early signs that it might help slow the progression of the disease over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350000, China
-
Massachusetts General Hospital
Boston, Massachusetts, 02467, United States
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100000, China
-
Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.